Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 6,076 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Metabolomic Study for Localized Prostate Cancer

NCT01968538
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

NCT02790125
View directory record Official record
Conditions
Healthy
Interventions
BMS-986166, Placebo matching BMS-986166
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

NCT04464239
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-142, TS-142 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Tapentadol in Post-Bunionectomy Pain

NCT01435577
View directory record Official record
Conditions
Bunion, Pain
Interventions
Tapentadol, Matching Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 2 Interventional

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT06785012
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-89495120, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 3:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

NCT03746067
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-134, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02185040
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones

NCT00576589
View directory record Official record
Conditions
Obesity
Interventions
CE-326,597, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Anaheim, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2010 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

NCT04886258
View directory record Official record
Conditions
Symptomatic Knee Osteoarthritis
Interventions
DFV890, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • El Cajon, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 29, 2026, 3:26 AM EDT
Recruiting Not applicable Interventional

The Impact of Melatonin Lotion on Sleep and Mental Health

NCT06768749
View directory record Official record
Conditions
Sleep Problems, Depressive Disorder and Anxiety Disorders
Interventions
Melatonin lotion, Placebo lotion
Other
Lead sponsor
University of Redlands
Other
Eligibility
18 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

NCT00568776
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Control, ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

NCT01552343
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Aventura, Florida • DeLand, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth

NCT06017050
View directory record Official record
Conditions
Bullying
Interventions
BullyDown, Attention-matched control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
12 Years to 14 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Clemente, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 29, 2026, 3:26 AM EDT
Terminated Phase 2 Interventional Results available

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
MLE4901, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Oceanside, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 29, 2026, 3:26 AM EDT
Terminated Phase 3 Interventional

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Batiraxcept, Paclitaxel, Placebo
Drug · Other
Lead sponsor
Aravive, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
84
States / cities
Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 29, 2026, 3:26 AM EDT
Completed Phase 1 Interventional

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

NCT04844450
View directory record Official record
Conditions
Fatty Liver Disease
Interventions
JNJ-75220795, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Hollywood, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 29, 2026, 3:26 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 29, 2026, 3:26 AM EDT